메뉴 건너뛰기




Volumn 341, Issue 3, 2012, Pages 702-708

A model-based approach to predicting the human pharmacokinetics of a monoclonal antibody exhibiting target-mediated drug disposition

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN RECEPTOR LIKE KINASE 1; MONOCLONAL ANTIBODY; PF 03446962; UNCLASSIFIED DRUG;

EID: 84861555037     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.112.191999     Document Type: Article
Times cited : (73)

References (19)
  • 1
    • 78751499845 scopus 로고    scopus 로고
    • Quantitative prediction of human pharmacokinetics for monoclonal antibodies: Retrospective analysis of monkey as a single species for first-in-human prediction
    • Dong JQ, Salinger DH, Endres CJ, Gibbs JP, Hsu CP, Stouch BJ, Hurh E, and Gibbs MA (2011) Quantitative prediction of human pharmacokinetics for monoclonal antibodies: retrospective analysis of monkey as a single species for first-in-human prediction. Clin Pharmacokinet 50:131-142.
    • (2011) Clin Pharmacokinet , vol.50 , pp. 131-142
    • Dong, J.Q.1    Salinger, D.H.2    Endres, C.J.3    Gibbs, J.P.4    Hsu, C.P.5    Stouch, B.J.6    Hurh, E.7    Gibbs, M.A.8
  • 3
    • 58149230979 scopus 로고    scopus 로고
    • TGF-beta signaling in vascular biology and dysfunction
    • Goumans MJ, Liu Z, and ten Dijke P (2009) TGF-beta signaling in vascular biology and dysfunction. Cell Res 19:116-127.
    • (2009) Cell Res , vol.19 , pp. 116-127
    • Goumans, M.J.1    Liu, Z.2    Ten Dijke, P.3
  • 5
    • 79951828866 scopus 로고    scopus 로고
    • Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies
    • Hu-Lowe DD, Chen E, Zhang L, Watson KD, Mancuso P, Lappin P, Wickman G, Chen JH, Wang J, Jiang X, et al. (2011) Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies. Cancer Res 71:1362-1373.
    • (2011) Cancer Res , vol.71 , pp. 1362-1373
    • Hu-Lowe, D.D.1    Chen, E.2    Zhang, L.3    Watson, K.D.4    Mancuso, P.5    Lappin, P.6    Wickman, G.7    Chen, J.H.8    Wang, J.9    Jiang, X.10
  • 6
    • 0003633755 scopus 로고    scopus 로고
    • Institute of Laboratory Animal Resources 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington DC
    • Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington DC.
    • (1996) Guide for the Care and Use of Laboratory Animals
  • 7
    • 0036900286 scopus 로고    scopus 로고
    • Antibody discovery: The use of transgenic mice to generate human monoclonal antibodies for therapeutics
    • Kellermann SA and Green LL (2002) Antibody discovery: the use of transgenic mice to generate human monoclonal antibodies for therapeutics. Curr Opin Biotechnol 13:593-597.
    • (2002) Curr Opin Biotechnol , vol.13 , pp. 593-597
    • Kellermann, S.A.1    Green, L.L.2
  • 8
    • 71449090902 scopus 로고    scopus 로고
    • Interspecies scaling of therapeutic monoclonal antibodies: Initial look
    • Ling J, Zhou H, Jiao Q, and Davis HM (2009) Interspecies scaling of therapeutic monoclonal antibodies: initial look. J Clin Pharmacol 49:1382-1402.
    • (2009) J Clin Pharmacol , vol.49 , pp. 1382-1402
    • Ling, J.1    Zhou, H.2    Jiao, Q.3    Davis, H.M.4
  • 9
    • 0033537831 scopus 로고    scopus 로고
    • Assignment of transforming growth factor beta1 and beta3 and a third new ligand to the type I receptor ALK-1
    • Lux A, Attisano L, and Marchuk DA (1999) Assignment of transforming growth factor beta1 and beta3 and a third new ligand to the type I receptor ALK-1. J Biol Chem 274:9984-9992.
    • (1999) J Biol Chem , vol.274 , pp. 9984-9992
    • Lux, A.1    Attisano, L.2    Marchuk, D.A.3
  • 10
    • 33746998477 scopus 로고    scopus 로고
    • ALK1 signalling analysis identifies angiogenesis related genes and reveals disparity between TGF-beta and constitutively active receptor induced gene expression
    • Lux A, Salway F, Dressman HK, Kröner-Lux G, Hafner M, Day PJ, Marchuk DA, and Garland J (2006) ALK1 signalling analysis identifies angiogenesis related genes and reveals disparity between TGF-beta and constitutively active receptor induced gene expression. BMC Cardiovasc Disord 6:13.
    • (2006) BMC Cardiovasc Disord , vol.6 , pp. 13
    • Lux, A.1    Salway, F.2    Dressman, H.K.3    Kröner-Lux, G.4    Hafner, M.5    Day, P.J.6    Marchuk, D.A.7    Garland, J.8
  • 11
    • 0035730322 scopus 로고    scopus 로고
    • General pharmacokinetic model for drugs exhibiting target-mediated drug disposition
    • DOI 10.1023/A:1014414520282
    • Mager DE and Jusko WJ (2001) General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn 28:507-532. (Pubitemid 34289541)
    • (2001) Journal of Pharmacokinetics and Pharmacodynamics , vol.28 , Issue.6 , pp. 507-532
    • Mager, D.E.1    Jusko, W.J.2
  • 13
    • 0032700670 scopus 로고    scopus 로고
    • Allometric issues in drug development
    • Mahmood I (1999a) Allometric issues in drug development. J Pharm Sci 88:1101-1106.
    • (1999) J Pharm Sci , vol.88 , pp. 1101-1106
    • Mahmood, I.1
  • 14
    • 0032822442 scopus 로고    scopus 로고
    • Prediction of clearance, volume of distribution and half-life by allometric scaling and by use of plasma concentrations predicted from pharmacokinetic constants: A comparative study
    • Mahmood I (1999b) Prediction of clearance, volume of distribution and half-life by allometric scaling and by use of plasma concentrations predicted from pharmacokinetic constants: a comparative study. J Pharm Pharmacol 51:905-910.
    • (1999) J Pharm Pharmacol , vol.51 , pp. 905-910
    • Mahmood, I.1
  • 15
    • 69949109408 scopus 로고    scopus 로고
    • Pharmacokinetic allometric scaling of antibodies: Application to the first-in-human dose estimation
    • Mahmood I (2009) Pharmacokinetic allometric scaling of antibodies: application to the first-in-human dose estimation. J Pharm Sci 98:3850-3861.
    • (2009) J Pharm Sci , vol.98 , pp. 3850-3861
    • Mahmood, I.1
  • 16
    • 23744475396 scopus 로고    scopus 로고
    • Pharmacokinetic-pharmacodynamic-efficacy analysis of efalizumab in patients with moderate to severe psoriasis
    • DOI 10.1007/s11095-005-5642-4
    • Ng CM, Joshi A, Dedrick RL, Garovoy MR, and Bauer RJ (2005) Pharmacokineticpharmacodynamic- efficacy analysis of efalizumab in patients with moderate to severe psoriasis. Pharm Res 22:1088-1100. (Pubitemid 41127066)
    • (2005) Pharmaceutical Research , vol.22 , Issue.7 , pp. 1088-1100
    • Ng, C.M.1    Joshi, A.2    Dedrick, R.L.3    Garovoy, M.R.4    Bauer, R.J.5
  • 18
    • 70349260659 scopus 로고    scopus 로고
    • Expression of vascular endothelial growth factor is coordinately regulated by the activin-like kinase receptors 1 and 5 in endothelial cells
    • Shao ES, Lin L, Yao Y, and Boström KI (2009) Expression of vascular endothelial growth factor is coordinately regulated by the activin-like kinase receptors 1 and 5 in endothelial cells. Blood 114:2197-2206.
    • (2009) Blood , vol.114 , pp. 2197-2206
    • Shao, E.S.1    Lin, L.2    Yao, Y.3    Boström, K.I.4
  • 19
    • 77955297665 scopus 로고    scopus 로고
    • Prediction of human clearance of therapeutic proteins: Simple allometric scaling method revisited
    • Wang W and Prueksaritanont T (2010) Prediction of human clearance of therapeutic proteins: simple allometric scaling method revisited. Biopharm Drug Dispos 31:253-263.
    • (2010) Biopharm Drug Dispos , vol.31 , pp. 253-263
    • Wang, W.1    Prueksaritanont, T.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.